DNA
Invirsa Science

Rethinking ocular and respiratory therapy.

After millions of years of co-evolution with multi-cellular organisms, the active molecule of INV-102 has become highly effective at triggering multiple targets associated with the DNA damage response.

Leadership Team

Robert ShalwitzLinkedIn

Robert Shalwitz, M.D.

Dr. Shalwitz is a pediatric endocrinologist with extensive background in clinical research and experience with the FDA. He has led teams to multiple successful new and supplemental drug approvals (NDAs and sNDAs) while at Abbott Laboratories and Reliant Pharmaceuticals. As one of the founders of both Akebia Therapeutics and Aerpio Therapeutics, Dr. Shalwitz participated in raising over $200 Million, including a successful public offering of Akebia.

Rachael WingoLinkedIn

Rachael Wingo, MBA

Rachael Wingo is an accomplished financial leader with success in the private equity and venture capital spaces. Rachael’s leadership experience spans business development, financial strategy and executive leadership at companies including Cardinal Health, Astute Solutions and Velosio. Rachael received her bachelor's degree and MBA from the University of Alabama.

Isaiah ShalwitzLinkedIn

Isaiah Shalwitz

Isaiah Shalwitz is a biostatistician and experienced program manager in pharmaceutical development. Isaiah worked in multiple aspects of pharmaceutical development during his eight-year tenure with Akebia Therapeutics. Most recently, Isaiah was the program manager for the team during non-clinical development, including IND enabling studies, of AKB-6899.

Cindy FlinnLinkedIn

Cindy Flinn, M.S.

Cindy Flinn is an experienced Program Leader, having managed numerous Drug Development programs from pre-clinical to late stage to include orphan drug development. She has worked in multiple therapeutic areas including infectious disease, Cardiovascular and Metabolic diseases at both startup and large established pharma companies. She was a successful project analyst and planner at Pfizer within the Research and Development Program.

Scientific Advisory Board

Kenneth Beckman

Kenneth Beckman, M.D.

Eric Donnenfeld

Eric Donnenfeld, M.D.

Beth Friedland

Beth Friedland, M.D.

Edward J. Holland

Edward J. Holland, M.D.

Marian Macsai

Marian Macsai, M.D.

Tim Willis

Tim Willis